To effectively accomplish the broad YCC programmatic reorganization, expansion of the ClinicalInvestigations program, and incorporation of operational oversight of Medical Oncology, the Center'sAdministration has itself been reconfigured, under new leadership. The primary responsibilities of theAdministration remain efficient provision of support and services requisite for efficient management of itsResearch Programs and Shared Resources, programmatic planning and evaluation, facilitation of researchactivities for YCC program members, fiscal management of the Center, strategic planning, and researchspace supervision and resource allocation. However, in parallel with the dramatic growth of the Center'sinfluence within the Medical Center, each of these component administrative activities have expanded inscope. For the past three years, the YCC Administration has been led by Ms. Nancy Scanlon, the DeputyDirector for Administration. Ms. Scanlon brings extensive past experience as chief administrator of a YaleMedical School department, with highly developed integrated academic, clinical practice, clinical investigativeand basic science research components. Her familiarity with institutional structure and function has beeninvaluable, as the domain of the YCC has substantially increased. Ms. Scanlon is supported by a team ofhighly skilled individuals with complementary expertise. YCC's administrative leadership is now moreprominently positioned in the Medical Center, with far more extensive interactions with Medical School,Hospital and University leadership. With a large contingent of new Research Program leaders, a new set ofYCC Associate Directors with newly defined responsibilities, a marked influx of recruited senior clinicalinvestigators, tightening of YCC membership criteria, and major augmentation of community relations andfundraising initiatives, the Administration has faced numerous challenges effectively. The responsibilities ofthe Center's Administration will continue to grow during the next project period, in order to continue to meetthe needs of increasingly active membership and expanding research base. The YCC employs approximately145 management and clerical staff members and has an overall operations budget of over $22 million of whichover $12 million is research related. This CCSG budget request is for 6% ($115,953) of the total YCCAdministration budget ($1.8 million).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016359-29
Application #
7513172
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-08-09
Project End
2012-07-31
Budget Start
2007-08-09
Budget End
2008-07-31
Support Year
29
Fiscal Year
2007
Total Cost
$101,733
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications